Merci, Monsieur le President. Thanks to the Minister for that, and I was careful with my question; I said how should it work in our jurisdiction, not how could it work or how will it work. That's okay.
In a related development, the federal government recently announced they are going to revise the rules and tools for the Patented Medicine Prices Review Board. In no way could that ever constitute a national pharmacare program, but the changes could result in the savings of billions of dollars on prescription medicine. Can the Minister tell us if his department knows about these developments with the Patented Medicine Prices Review Board and what we're doing to look at the impacts of these changes on our healthcare system? Mahsi, Mr. Speaker.